UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib

被引：1
|
作者：
Miura, S. [1 ]
Maerten, A. [2 ]
Popat, S. [3 ,4 ]
机构：
[1] Niigata Univ, Dept Homeostat Regulat & Dev, Div Resp Med, Niigata, Japan
[2] Boehringer Ingelheim Int GmbH, Dept Med, Ingelheim, Germany
[3] Royal Marsden Natl Hlth Serv Fdn Trust, Lung Unit, London, England
[4] Inst Canc Res, London, England
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.466
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
420TiP
引用
收藏
页码：S1405 / S1406
页数：2
相关论文
共 50 条
  • [1] UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations
    Miura, S.
    Hsia, T-C.
    Hung, J-Y.
    Jung, H. A.
    Shih, J-Y.
    Yang, T-Y.
    Park, C-K.
    Lee, S. H.
    Okamoto, T.
    Ahn, H. K.
    Lee, Y. C.
    Sato, Y.
    Lee, S. S.
    Mascaux, C.
    Daoud, H.
    Maerten, A.
    Popat, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S776 - S777
  • [2] UpSwinG: real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations.
    Miura, Satoru
    Hsia, Te-Chun
    Hung, Jen-Yu
    Jung, Hyun Ae
    Shih, Jin-Yuan
    Yang, Tsung-Ying
    Park, Cheol-Kyu
    Lee, Seung Hyeun
    Okamoto, Tatsuro
    Ahn, Hee Kyung
    Lee, Yong Chul
    Sato, Yuki
    Lee, Sung Sook
    Mascaux, Celine
    Daoud, Hasan
    Maerten, Angela
    Popat, Sanjay
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [3] Afatinib in patients with EGFR mutation-positive (EGFRm plus ) NSCLC harbouring uncommon mutations: Experience in 'Real-World' clinical practice
    Maerten, Angela
    Brueckl, Wolfgang
    Laack, Eckhart
    Hoffmann, Christopher
    Zhou, Caicun
    Wu, Yi-Long
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 160 - 160
  • [4] Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm plus ) advanced NSCLC: Updated data from the GioTag real-world study
    Hochmair, M. J.
    Morabito, A.
    Hao, D.
    Yang, C-T.
    Soo, R.
    Yang, J. C-H.
    Gucalp, R.
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    Cufer, T.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [5] Afatinib in EGFR Mutation-Positive (EGFRm plus ) NSCLC Harbouring Uncommon Mutations: Experience in 'Real-World' Clinical Practice
    Brueckl, W.
    Laack, E.
    Hoffmann, C.
    Zhou, C.
    Wu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S670 - S671
  • [6] Afatinib Followed by Osimertinib in Real-World Patients with EGFR Mutation-Positive Advanced NSCLC: The Giotag Study
    Hochmair, M. J.
    Morabito, A.
    Hao, D.
    Yang, C.
    Soo, R.
    Yang, J. C.
    Gucalp, R.
    Halmos, B.
    Golembesky, A.
    Maerten, A.
    Cufer, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1045 - S1045
  • [7] Afatinib followed by osimertinib in patients with EGFR mutation-positive advanced NSCLC: A real-world study (GioTag)
    Hochmair, M. J.
    Morabito, A.
    Hao, D.
    Yang, C-T.
    Soo, R. A.
    Yang, J. C-H.
    Gucalp, R.
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    Cufer, T.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [8] Afatinib in Patients with EGFR Mutation-Positive (EGFRm plus ) NSCLC Harboring Uncommon Mutations: Overview of Clinical Data
    Arrieta, O.
    De Marchi, P.
    Yamamoto, N.
    Yu, C.
    Ou, S. I.
    Zhou, C.
    Paskevicius, M.
    Maerten, A.
    Wu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S165 - S165
  • [9] Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm plus ) NSCLC: Final analysis of Asian patients in the GioTag study
    Hochmair, M. J.
    Morabito, A.
    Hao, D.
    Yang, C-T.
    Soo, R. A.
    Yang, J. C-H.
    Gucalp, R.
    Halmos, B.
    Marten, A.
    Cufer, T.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1399 - S1399
  • [10] Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study
    Hochmair, M.
    Cufer, T.
    Morabito, A.
    Hao, D.
    Yang, C.
    Soo, R.
    Yang, J. C.
    Gucalp, R. Rasim
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    O'Byrne, K.
    [J]. LUNG CANCER, 2019, 127 : S37 - S37
12345